Michael Hodsdon

Michael Hodsdon is the Vice President of Clinical Diagnostics at Eli Lilly & Company, where they currently lead a mass spectrometry-focused biomarker discovery and clinical implementation group. They possess extensive experience as a Clinical Pathologist (MD/PhD), having previously served as a Clinical Laboratory Medical Director and biomedical researcher. At Eli Lilly, Michael managed groups of physicians and scientists and oversaw the transfer, validation, and performance of immunogenicity and biomarker assays. Their prior roles include positions at Yale New Haven Hospital and Yale University School of Medicine, where they contributed to clinical chemistry and research. Michael co-founded M/Z Diagnostics and has been instrumental in developing and implementing immunogenicity assessment strategies throughout their career.